FDA-cleared profile

Rayvolve

AZmed SAS

Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.

Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.

Clinical details

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and emergency physicians.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Care setting and population
Radiology and emergency-care review of adult and pediatric patients aged 2 years or older.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Detection, localization, or diagnostic support; aided diagnosis and not autonomous operation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM radiographs from a DICOM Node or PACS, limited to the FDA-listed musculoskeletal study types and standard views: ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Output and human action
Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
Rayvolve does not replace medical doctors. Performance figures are endpoint- and population-specific; K240845 reports no new clinical study and references the predicate Rayvolve clinical-reader study. Local DICOM/PACS compatibility, commercial security, price, and service terms require qualification.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240845
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
MSK
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Controlled anatomy normalization from the listed osteoarticular study types.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-07-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA packet describes current-edition DICOM interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with prediction output delivered as a processed DICOM image after the original.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Specific interface versions, routing, viewer behavior, and local compatibility remain acceptance-test items.

Deployment and data flow
On-premise or cloud platform connected to the radiology center local network and DICOM Node server.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary does not establish current hosting region, retention, security controls, uptime, or commercial configuration.

Security and privacy
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-07

The FDA comparison table contains a privacy characteristic, but the reviewed sources do not establish the current commercial security architecture, retention, access controls, audit, or incident-response terms.

Training and support
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-07

The FDA packet says instructions for use are transmitted and used to train users; current onboarding, competency, and support commitments were not established.

Monitoring and change control
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-07

Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.

DICOM Node and PACS workflow

The exact FDA packet describes interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with the original image followed by the processed image containing fracture prediction and localization.

exact submission · checked 2026-09-07

Test representative identifiers, routing, image ordering, annotation toggles, and failure handling locally.

Deployment options

The FDA packet describes on-premise and cloud operation connected to the radiology center local network and DICOM Node server.

exact submission · checked 2026-09-07

Current hosting, PHI flow, retention, and service commitments are not established.

Current family workflow

AZmed's current Rayvolve page describes local PACS/workflow integration in a radiology customer testimonial and presents Rayvolve as an AI second opinion for fracture detection.

product family · checked 2026-09-07

Vendor page and testimonial; it does not establish a specific connector, PACS version, SLA, or local deployment result.

Independent assessment context

The NIHR/NICE early value assessment table describes Rayvolve in the assessed NHS context as using DICOM radiographs and integrating into existing hospital radiology workflows through Wellbeing's AI Connect gateway. That assessment lists Rayvolve as adult-only for its evaluated context, whereas the exact K240845 FDA indication includes pediatric patients aged 2 years or older.

product family · checked 2026-09-07

Historical assessment context; do not use it to narrow or expand the exact FDA indication without the K240845 packet.

Current NICE evidence-generation controls

NICE HTG739 conditionally recommends Rayvolve for use in NHS urgent care while evidence is generated and calls for local disagreement protocols plus monitoring of accuracy, software failures, downstream referrals, treatment changes, implementation cost, subgroups, and postmarket surveillance.

product family · checked 2026-09-08

English NHS health-technology guidance; not exact K240845 pricing, reimbursement, or US adoption evidence.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA submission reports standalone pediatric performance on 3,016 radiographs across all indicated study types and views: sensitivity 0.9611, specificity 0.8597, and ROC-AUC 0.9399. The submission states that no new clinical study was conducted for K240845 and references the predicate Rayvolve clinical reader study separately.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

The 3,016-case results are standalone pediatric testing; do not merge them with predicate adult clinical-reader results.

Reported sensitivity
96.11% (95% Wilson CI 94.80%-97.10%) in the exact FDA standalone pediatric dataset.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Endpoint is image-level standalone sensitivity for the pediatric dataset; the structured metric records the paired specificity and AUC separately.

Reported specificity
85.97% (95% Wilson CI 84.34%-87.45%) in the exact FDA standalone pediatric dataset.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Endpoint is image-level standalone specificity for the pediatric dataset.

Standalone sensitivity

0.9611 proportion

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Standalone specificity

0.8597 proportion

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Standalone ROC-AUC

0.9399 ROC-AUC

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Rayvolve pediatric standalone performance assessment

  • DesignStandalone performance assessment
  • PopulationPediatric patients aged 2 years or older across the indicated musculoskeletal study types and views
  • Scopeexact submission
  • Tested versionRayvolve (K240845)
  • Samplen=3016
  • IndependenceIndependence not established

K240845

The FDA packet states that no clinical study was conducted in support of K240845; this standalone assessment supported inclusion of the pediatric population.

Rayvolve regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult and Pediatric
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240845
  • Samplen=3016
  • IndependenceIndependence not established

K240845

Baseline ACR summary retained; FDA packet details above control endpoint and pediatric scope.

Costs and setup

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-07

No current exact-product price or contract terms were established from the reviewed public sources. The NICE assessment used a notional cost input, not a vendor quote.

Reimbursement and coding
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.

No product-specific code

NICE HTG739 conditionally recommends Rayvolve for NHS use during a two-year evidence-generation period, subject to evidence-generation agreements and appropriate regulatory and DTAC approval; this is not a reimbursement determination.

NICE guidance for the NHS in England · England · Effective 2025-01-14

NICE's exploratory model uses GBP 1 per scan and says actual software, implementation, and postmarket costs are uncertain. This is not a vendor quote or US coverage evidence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
28Fields reviewed
10Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The stored evidence-candidates metadata and identifier lists were screened in order. This was metadata screening, not a full paper or ClinicalTrials.gov record review; no candidate abstract or full text is promoted here. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, health technology assessment, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources & history

How this profile was documented

Open the ledger for source dates, scope, and research-record updates.

View source ledger and history

Source ledger

  1. K240845 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rayvolve model card (K240845)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) K240845: Rayvolve

    U.S. Food and Drug Administration - Published 2024-07-17 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  8. Rayvolve AI Suite

    AZmed - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, PACS, implementationCapabilities

  9. NIHR/NICE early value assessment of AI fracture detection on X-rays

    National Institute for Health and Care Research / NICE - Accessed 2026-09-07

    Scope: productFamily, implementationContext, populationContext

  10. NICE HTG739: AI technologies to help detect fractures on X-rays in urgent care

    National Institute for Health and Care Excellence - Published 2025-01-14 - Accessed 2026-09-08

    Scope: conditionalAdoption, economics, evidenceGaps, implementationCapabilities

Research history

  1. K240845 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K242171

TechCare Trauma

Milvue

Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle,...

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-01-17
FDA-cleared K193417

FractureDetect (FX)

Imagen Technologies, Inc.

FractureDetect (FX) is a computer-assisted detection and diagnosis (CAD) software device to assist clinicians in detecting fractures during the review of radiographs of the...

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2020-07-30
FDA-cleared K251408

OsteoSight™ Hip (v1)

Naitive Technologies Ltd

Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset...

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-09-02
FDA-cleared K202487

HealthJOINT

Zebra Medical Vision Ltd.

The Zebra HealthJOINT device is a software tool for 3D reconstruction of bones from a set of 2D radiographs. The device is intended for assisting clinicians in the preoperative...

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2020-12-04